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Case Report 
A 76-year-old postmenopausal woman presented to E.R. 
department with a 4 months history of bilateral pain at the thigh and 
the patient had to walk using a crutch [1,2]. !e patient had a small 
trauma on the le" side: at the beginning it was performed only le" leg 
X-Rays that revealed a displaced fracture in mid-thigh (Figure 1).
Patient was on Alendronic Acid 70 mg once a week for 
postmenopausal osteoporosis for more than 5 years.
On #rst physical examination, there was a severe bilateral pain in 
mid-thigh: it was performed a X-Ray of right femur showing a lateral 
cortex thickening and a transverse fracture line of the mid-thigh 
(Figure 2). 
!e patient used vitamin D supplies but vitamin D (25-OH) blood 
level was very low. 
!e patient was referred to Orthopaedic Surgery and underwent the 
closed reduction and internal #xation with IMHS (Intra Medullary Hip 
Screw) to both femoral sha"s (Figures 3 and 4). Surgery outcome was 
good with no complications. !e patient was kept under observation 
with 25-hydroxycholecalciferol (Calcifediol) supplementation. !e 
clinic follow-up was based on periodic examinations and 1-3-6-12 
months postoperative X-Rays (Figures 5-10).
!e patient was discharged ambulating using two crutches with no 
pain. Active hip $exion 90 degrees and passive 100 degrees. 
Discussion
AFF can occur in patients treated with long-term alendronate 
therapy [3].!e incidence of these kind of fractures is estimated in 78 
cases per 100,000 patients taking oral bisphosphonates [4] for more 
than 5 years [5,6].
!e half-life of bisphosphonate is more than 10 years and it exerts 
its e%ects even a"er cessation of therapy [4]. 
!e ability of bone to remodel may be impaired by long term 
administration of bisphosphonate because it induces prolonged 
suppression of bone turnover, accumulation of micro-damage and it 
compromises the bone strength and leads to insu&ciency stress fracture 
[7], but the AFF pathogenetic mechanism has not been de#ned yet.
!e American Society for Bone and Mineral Research (ASBMR) 
task force suggested several possibile pathogenic mechanisms [7]:
Figure 1: Left leg X­Ray.
1. Alteration of the normal pattern of collagen cross-linking.
2. Micro-damage accumulation.
3. Increased mineralization.
4. Reduced heterogeneity of mineralization.


















1. Generalized increase in cortical thickness of the femoral 
diaphysis.
2. Unilateral or bilateral prodromal symptoms, such as dull or 
aching pain in the groin or thigh.
3. Bilateral incomplete or complete femoral diaphysis fracture.
4. Delayed healing.
We can diagnose AFF if major criteria exist.
Pain, typically sharp, well-localized to the mid or upper thigh, for 
several weeks to months prior to the fracture are prodromal clinical 
features. As described by Rizzoli et al. [8] fractures occur with minimal 
or no trauma and Giusti et al. [3] reported about 40% of these fracture 
occurred with no trauma history. When a patient has such a kind of 
features in a long-term alendronate therapy the #rst exam to perform is 
bilateral radiographs of the femur looking for stress reaction and then 
if necessary MRI.
!e clinical features of these fractures are prodromal pain, 
typically sharp, well-localized to the mid or upper thigh, for several 
weeks to months prior to the fracture [3]. As described by Rizzoli et 
al. [8] fractures occur with minimal or no trauma and Giusti et al. [3] 
reported about 40% of these fracture occurred with no trauma history. 
!erefore, critical evaluation of patients on long-term bisphosphonate 
therapy presenting with pain in the thigh is required. Routine bilateral 
radiographs of the femur looking for stress reaction is required and if 
necessary, advanced imaging such as bone scan or magnetic resonance 
imaging should be considered. Silverman and Christiansen [1] 
proposed the concept of a “drug holiday”, based on evidence of sustained 
protection from increased bone turnover and fracture in patients who 
had received bisphosphonate therapy 5 or more years. 
Conclusion
In conclusion, we suggest discontinuation of long-term 
bisphosphonate therapy a"er 4-5 years in patient with osteoporosis and, 
in case of thigh pain, we ask for X-Rays in order to con#rm the diagnosis 
of AFF. !e orthopedic surgical therapy can be closed reduction and 
internal #xation. Orthopedic follow-up is based on periodic clinical 
examinations and 1-3-6-12 months postoperative X-Rays. 
6. Reduced vascularity and anti-angiogenic e%ect.
!e ASBMR set major and minor diagnosis criteria.
!e major criteria are:
1. !e fracture is associated with no or minimal trauma, as in a fall 
from standing height or less.
2. !e fracture line originates at the lateral cortex and is substantially 
transverse in its orientation, although it may become oblique as 
it progresses medially across the femur.
3. Complete fractures extend through both cortices and may be 
associated with a medial spike, whereas incomplete fractures 
involve only the lateral cortex.
4. !e fracture is un-comminuted or minimally comminuted.
5. Localized periosteal or endosteal thickening of the lateral cortex 
is present at the fracture site (“breaking” or “$aring”).
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